Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
CD164 CRISPR/Cas9 KO Plasmid (m): sc-424720
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CD164 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the CD164 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CD164 Antibody (H-4): sc-271179
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD164 CRISPR/Cas9 KO Plasmid (m) | sc-424720 | 20 µg | $397.00 |
Overview
Cd164 encodes CD164, a sialomucin cell-surface glycoprotein that supports cell adhesion and regulates trafficking of hematopoietic and other progenitor cells within tissue microenvironments. CD164 participates in endosomal transport and receptor organization at the plasma membrane, influencing signaling and migratory behavior in pathways linked to stem cell niche interactions. In mouse models, altered Cd164 expression or function is studied in the context of hematopoiesis, immune cell development, and tissue remodeling. Dysregulated CD164 has been associated with changes in proliferation, invasion, and microenvironmental crosstalk relevant to cancer biology and inflammatory disease mechanisms.
CD164 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Cd164 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Cd164 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Cd164 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish CD164 protein expression.
This CRISPR knockout system enables efficient generation of Cd164-deficient cell models for investigation of CD164 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Cd164 exon(s) critical for CD164 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Cd164 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by CD164 CRISPR/Cas9 KO Plasmid (m) and CD164 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Cd164 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by CD164 HDR Plasmid (m) and CD164 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Cd164 homology arms to support homology-directed repair at defined Cd164 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.